Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients

Abstract

In Asian patients, pegfilgrastim prophylaxis did not show a therapeutic advantage for preventing neutropenic outcomes compared with filgrastim prophylaxis.

Clinical pharmacy services and research for lymphoma patients at a cancer center

“…This study demonstrated that the incidences of breakthrough FN are relatively similar with the two agents (pegfilgrastim: 16.3% vs filgrastim: 13.6%, p ¼ 0.69) ( Table 1), and concluded that either G-CSF can be administered to NHL patients, with usage being largely guided by patient preference. 4 Although the study results have shown that filgrastim and pegfilgrastim have similar efficacies for the prevention of FN in NHL patients, approximately 15% may still experience breakthrough FN. Hence, another epidemiological study was performed to evaluate the risk factors associated with breakthrough FN among patients who received pegfilgrastim prophylaxis for CHOP-based chemotherapy.…”

“…Comparison of efficacy between filgrastim and pegfilgrastim prophylaxis (adapted from Chan et al4 ).…”

Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy

“…Patient data from four different studies (including patients with breast cancer and lymphoma receiving chemotherapy) were pooled in this analysis. [3][4][5][6] The data included demographics, disease-related and chemotherapy-related parameters, medical histories of other co-morbid diseases, as well as laboratory information reflective of hepatic, renal and hematological functions. Patients were treated with a variety of taxane-based, anthracycline-based and etoposidebased chemotherapy regimens.…”

“…2 In Singapore, the incidence of FN among breast and lymphoma patients receiving myelosuppressive chemotherapies ranges from 6.3 to 25.0%. [3][4][5][6] Events resulting from FN may also be associated with an increased financial burden and risk of mortality. 7 The prophylactic use of granulocyte colony-stimulating factors (G-CSFs) can lead to a significant reduction of the incidence, duration and severity of chemotherapy-induced neutropenia and its complications.…”

Supportive Care in Cancer Patients: Current Challenges and Opportunities

“…Two pharmacoepidemiology studies that were conducted within Asian lymphoma patients demonstrated that, the incidence of breakthrough FN in lymphoma patients remained high even after receiving prophylactic pegfilgrastim, ranging from 13-16% [4,5]. It is unknown why lymphoma patients manifested breakthrough FN -whether it is due to the lack of adequate pegfilgrastim exposure or the lack of antimicrobial prophylaxis.…”